The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna

Barbara Kiesewetter, Markus Raderer, Gerald W Prager, Thorsten Fuereder, Christine Marosi, Matthias Preusser, Michael Krainer, Gottfried J Locker, Thomas Brodowicz, Christoph C Zielinski

To cite: Kiesewetter B, Raderer M, Prager GW, et al. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open 2017;2:e000166. doi:10.1136/esmoopen-2017-000166

ABSTRACT

Background The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a new tool to quantify the clinical benefit that may be anticipated from a novel anticancer treatment. We present here an analysis on the feasibility of the ESMO-MCBS in less frequent tumour entities.

Methods This study evaluates the practicability of the ESMO-MCBS for metastatic neuroendocrine tumours (NETs), soft tissue sarcomas, glioblastoma, thyroid cancer, pancreatic cancer, head/neck cancer, urothelial cancer and ovarian cancer at the Medical University Vienna. A three-step approach including data acquisition, assessment of ESMO-MCBS scores and evaluation of results with a focus on clinical feasibility was applied.

Results In NET and thyroid cancer, all analysed trials were very comparable in design and efficacy, and the ESMO-MCBS scores appeared to be consistent with the clinical benefit seen in practice. For pancreatic cancer, it was more difficult to compare first-line trials due to diverging populations included in the respective studies. Concerning soft tissue sarcomas, the ESMO-MCBS was applicable for gastrointestinal stromal tumours (GIST) and ‘non-GIST’ soft tissue sarcoma with respect to data deriving from randomised studies. However, due to the heterogeneity of the disease itself and a limited number of controlled trials, limitations are noted. In ovarian cancer, the ESMO-MCBS supported the use of bevacizumab in high-risk patients. To date, there are only limited data for glioblastoma, head/neck cancer and urothelial cancer but whenever randomised trials were available, the ESMO-MCBS rating supported clinical decisions. Interestingly, nivolumab for salvage treatment of head/neck cancer rated extremely high.

Conclusion The ESMO-MCBS scores supported our common treatment strategies and highlight the potential of new immunomodulatory drugs. Our results encourage further development of the ESMO-MCBS.

Key questions

What is already known about this subject? The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) has been developed aiming to provide a standardised, generic and validated approach to stratify the potential clinical benefit that may be anticipated from a novel anticancer treatment. The score has been internally validated in a selection of trials during the initial development process and recently in a pilot field-testing on common tumour entities at our institution.

What does this study add? We report a ‘real-life’ experience of the ESMO-MCBS applied for treatment decisions in metastatic neuroendocrine tumours, soft tissue sarcomas, glioblastoma, thyroid cancer, pancreatic cancer, head/neck cancer, urothelial cancer and ovarian cancer at the Medical University of Vienna. In line with our recent report on common tumour entities, most scores assessed corresponded well with the daily clinical experience at our institution. The results supported both the use of the ESMO-MCBS and our current treatment standards. Furthermore, the ESMO-MCBS highlighted the high clinical benefit to be expected from novel immunomodulatory treatment options exemplified by immune checkpoint inhibitors. However, limitations were noted in case of cascade like treatment settings, orphan diseases or scenarios in which trials of most efficacious treatments are missing (e.g., in the first-line treatment of pancreatic cancer).

How might this impact on clinical practice? Our results encourage further development of the ESMO-MCBS and illustrate how the score may be applied in daily clinical practice. In addition, we highlight potential limitations that have to be considered.
INTRODUCTION

The European Society for Medical Oncology (ESMO) - Magnitude of Clinical Benefit Scale (MCBS) has been developed by a taskforce of renowned European medical oncologists aiming to provide a standardised, generic and validated approach to stratify the potential clinical benefit that may be anticipated from a novel anticancer treatment based on original data extracted from randomised or controlled clinical trials.1

While due to the enormous velocity in clinical drug development in recent months, several institutions worldwide have made strong efforts to evolve concepts, scores or scales for stratification of new treatment approaches, the ESMO-MCBS appears somehow unique as it concentrates particularly on the clinical benefit to be expected for the individual patient irrespective of socioeconomic factors.1–3 In addition, it is easy to use for the qualified clinician based on forms publicly available on the ESMO homepage and allows on-time evaluation of new data on a regular basis.4 Key points requested during assessment of the ESMO-MCBS scores include the primary endpoint of the specific study in terms of absolute gain in progression-free survival (PFS) or overall survival (OS) in months and the corresponding 95% CI of the HR; in a second step, information about toxicity and quality of life (QOL) is added if available. The concept offers different forms for curative and palliative care setting and has adapted versions with respect to duration of response in the control arm. Following this process, the user is provided with a recommendation level of ‘1–5’ in the palliative and ‘A’ to ‘C’ in curative scenarios with ‘4–5’ and ‘A’ corresponding to a high level of benefit and ‘C’/‘1’ identifying treatment regimens that are considered non-recommended.1

Being introduced for the first time by the middle of 2015 by ESMO, the ESMO-MCBS has excited great public interest in the last year. However, we felt that due to the fact that the score has only been internally validated in a selection of trials during the development process, a further assessment of reproducibility under real-life conditions would be necessary prior to implementation in daily practice. Consequently, we have recently conducted a systematic field testing of the ESMO-MCBS at the Medical University of Vienna (MUV) including data on advanced breast cancer, lung cancer, colorectal cancer, prostate cancer and renal cell cancer.5 We could demonstrate that in the majority of cases, the ESMO-MCBS scores are consistent with clinical practice at our institution and are particularly in line with our first-line standards for common tumour entities like metastatic breast cancer, colorectal cancer or lung cancer. Thus, the score appeared to be feasible and useful for daily practice in a tertiary centre.

In addition to our personal experience at the MUV, Giuliani and colleagues from Italy6 have presented their experience with pivotal phase III randomised trials on tyrosine-kinase inhibitors (TKIs) first line for advanced lung cancer with activating epidermal growth factor receptor mutations. In line with our data, they have observed a high level of recommendation for compounds in regular use and suggested combination with pharmacological costs to gain additional socioeconomic information by use of the ESMO-MCBS.

Based on these promising results and the positive resonance we have received for our pilot trial on common tumour subtypes, we present here an extended analysis on the feasibility of the ESMO-MCBS in relatively rare tumour entities. These include our results on neuroendocrine tumours (NETs), thyroid cancer, pancreatic cancer, head and neck cancer, glioblastoma, ovarian cancer, urothelial cancer and soft tissue sarcomas (STS).

METHODS

This study evaluated the clinical applicability and practicability of the ESMO-MCBS in less frequent tumour entities in general and at the MUV, Clinical Division of Oncology and the Comprehensive Cancer Center, a tertiary referral centre for oncological diseases, in particular. Based on the concept developed for the testing of frequent tumour entities, we have used a three-step approach including data acquisition, assessment of ESMO-MCBS scores and evaluation of results with a focus on clinical feasibility.

Step one: data acquisition

A systematic data collection of intravenously and orally applied anticancer drugs in regular use at the MUV over a period of 2 months was performed. Treatment protocols and applied regimens including cytostatic agents, antibodies and immunotherapeutic compounds were extracted from CATO (computer aided therapy for oncology), a software technology routinely used for managing administration of oncological therapies at our clinic. Tumour subtypes evaluated in this study were locally advanced or metastatic NETs of the gastrointestinal (GI) tract and lung, thyroid cancer, pancreatic cancer, squamous-cell cancer of the head and neck (non-nasopharyngeal), glioblastoma, ovarian cancer, urothelial cancer and STS (all histologies, including gastrointestinal stromal tumours (GIST)). This selection of tumour entities is based on the clinical focus of our department and includes only entities accounting for less than 5% of all cancer cases in Europe.7 Data were subdivided per treatment setting from first line to salvage therapy. (Neo-) Adjuvant treatment strategies were excluded due to strict compliance to guidelines in these settings.

Step two: ESMO-MCBS assessment

A literature search was conducted to assess source data for treatment approaches identified in step one (i.e., trials identified as reference for the established treatment protocols at our department). While we have systematically analysed and investigated data relevant to the daily routine at our department, it must be clearly stated that we aimed to provide a thorough ‘one-centre’ experience but not a complete work-up of oncological therapies.
available. The data presented here are a selection of trials considered essential for practice at our clinic. Randomised or controlled clinical trials (comparative cohort design) were scored with the ESMO-MCBS forms for the palliative treatment setting using versions 2A, 2B or 2C based on the primary endpoint of the trial. All scores were assessed by BK and re-evaluated by the senior medical oncologists for the respective tumour entity. Results are referred to as MCBS field testing (MCBS-FT score) throughout the manuscript. In case of pre-evaluation of a trial in the internal validation cohort of the ESMO taskforce, those results were adopted and rechallenged according to local standards (referred to as ESMO-MCBS score). As outlined in the original version of the ESMO-MCBS, scores of 4 and 5 were accepted as high level of recommendation. Trials that failed to demonstrate statistical significance of evaluated outcomes are not eligible for ESMO-MCBS assessment but documented in this analysis if relevant to our practice (referred to as ‘not applicable’).

**Step three: feasibility assessment**

We have performed interviews to review data and results with the tumour entity specific programme directorships (PDs) (=senior medical oncologist) and their coworkers covering the distinct tumour entities within specialised subunits. ESMO-MCBS results and recommendation levels were reassessed and checked for completeness, significance and clinical feasibility. Each PD had to address the following points: (1) Do the ESMO-MCBS scores correlate with the clinical experience? (2) Does the ESMO-MCBS support treatment decisions in daily practice? (3) What are the potential limitations of the ESMO-MCBS? The consensus was then summarised in the conclusion section of each tumour entity.

**RESULTS**

**Neuroendocrine tumours**

Data of locally advanced/metastatic NETs were subdivided into common treatment strategies for midgut/lung NET and pancreatic NET, respectively (table 1).8–15

**Assessment of ESMO-MCBS**

Assessment of ESMO-MCBS scores for advanced NET revealed comparable results in all available data (all trials placebo controlled). The CLARINET and the PROMID trial represent two proof of principle studies demonstrating for the first time direct antiproliferative effects of somatostatin analogues for advanced midgut and pancreatic NET irrespective of progression status.8,9 For both, lanreotide (median PFS gain +32% at 2 years; median HR 0.47, 95% CI 0.30 to 0.73) and octreotide (PFS gain 8.3 months; HR 0.34, 95% CI 0.20 to 0.59), a significant increase in PFS was documented. QOL data confirmed maintenance of QOL in the treatment arm, but no improvement was documented (downgrade 1 point). Documented toxicity was low, and no downgrading for adverse events (AEs) was indicated resulting in a final MCBS-FT score of 2. Everolimus was equally effective in adverse events (AEs) was indicated resulting in a final improvement was documented (downgrade 1 point).

**Thyroid cancer**

Data of locally advanced/metastatic thyroid cancer were subdivided into common treatment strategies for medullary thyroid cancer and well-differentiated iodine-refractory thyroid cancer, respectively (table 2).16–19

In the case of medullary thyroid cancer, there are currently two TKIs of interest.16 17 Both compounds were analysed in comparable randomised trials powered for an endpoint of PFS. For cabozantinib, the median PFS gain was 7.2 months (HR 0.28, 95% CI 0.19 to 0.40). Toxicity was high with 20% increase in serious AEs diminishing the expected clinical benefit (downgrade 1 point, MCBS-FT score 2).16 Vandetanib showed an improvement of 11.2 months in PFS (HR 0.46, 95% CI 0.31 to 0.69).17 Decleration of toxicities was not clear in this publication so it is debatable whether downgrading of the final ESMO-MCBS score is required (MCBS-FT score 2–3).

Lenvatinib for progressive, iodine-refractory differentiated thyroid cancer showed a high median PFS of 18.3 months versus 3.6 months in the control arm (HR 0.21, 95% CI 0.14 to 0.31), but again significantly more toxicities including toxic deaths were documented (downgrade 1 point, MCBS-FT score 2).18 Similarly, sorafenib (PFS gain 5 months; HR 0.59; 95% CI 0.45 to 0.76) resulted in more than 10% increase in serious AEs (downgrade 1 point, MCBS-FT score 2).19
Table 1 FT of the ESMO-MCBS for the treatment of neuroendocrine tumours at the Medical University of Vienna

| Analysed treatment                                      | Setting                                      | Primary EP | PFS control | PFS gain   | PFS HR     | OS control | OS gain | OS HR | Adjustment/ Remark | MCBS | MCBS-FT |
|----------------------------------------------------------|----------------------------------------------|------------|-------------|------------|------------|------------|---------|-------|---------------------|------|---------|
| Lanreotide versus placebo (CLARINET) Caplin et al, NEJM<sup>8</sup> | Ki-67<10% Gl or unknown origin (non-functioning) | PFS        | 18 months   | +32% at 2 year | 0.47 (0.30–0.73) |           |         |       | No improvement in QOL, downgrade 1 point | –    | 2       |
| Octreotide versus placebo (PROMID) Rinke et al, JCO<sup>9</sup> | Midgut, unknown (non-functioning and functioning) | TTP        | 6 months    | 8.3 months | 0.34 (0.20–0.59) |           |         |       | No improvement in QOL, downgrade 1 point | –    | 2       |
| Everolimus versus placebo (RADIANT-4) Yao et al, Lancet<sup>10</sup> | Progressive disease lung or GI (non-functioning) | PFS        | 3.9 months  | 7.1 months | 0.48 (0.35–0.67) |           |         |       | –                   | 3    |         |
| Everolimus versus placebo (RADIANT-3) Yao et al, NEJM<sup>11</sup> | Progressive disease pancreatic NET          | PFS        | 4.6 months  | 6.4 months | 0.35 (0.27–0.45) | 37.7m     | 6.3m    | Non-significant | –    | 3       |
| Octreotide ± everolimus (RADIANT-2) Pavel et al, Lancet<sup>13</sup> | Progressive disease lung, Gl, unknown (functioning) | PFS        | 11.3 months | 5.1 months | Non-significant |           |         |       | –                   | NA   |         |
| Sunitinib versus placebo Raymond et al, NEJM<sup>14</sup> Faiivre et al, JCO<sup>15</sup> | Progressive pancreatic NET                  | PFS        | 5.5 months  | 5.9 months | 0.42 (0.26–0.66) | 29.1m     | 9.5m    | Non-significant | No improvement in QOL, downgrade 1 point | –    | 2       |

EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; GI, gastrointestinal; MCBS, Magnitude of Clinical Benefit Score; NA, not applicable; NET, neuroendocrine tumour; OS, overall survival; PFS, progression-free survival; QOL, quality of life; TTP, time to progression.
Table 2: FT of the ESMO-MCBS for the treatment of thyroid cancer at the Medical University of Vienna

| Analysed treatment          | Setting                              | Primary EP | PFS control | PFS gain | PFS HR (95% CI) | OS gain | OS HR (95% CI) | Adjustment/remark | MCBS | MCBS-FT |
|-----------------------------|--------------------------------------|------------|-------------|----------|----------------|---------|----------------|-------------------|------|---------|
| Cabozantinib versus placebo | Progressive disease medullary thyroid cancer | PFS        | 4 months    | 7.2 months | 0.28 (0.19-0.40) |         |                | 42% versus 23% SAE, downgrade 1 point | 2    |          |
| Elisei et al, JCO\(^{16}\)  |                                      |            |             |           |                |         |                |                   |      | 2       |
| Vandetanib versus placebo   | Medullary thyroid cancer              | PFS        | 19 months   | 11.2 months | 0.46 (0.31-0.69) |         |                | More grade III/IV AEs | -    | 2–3*    |
| Wells et al, JCO\(^{17}\)   |                                      |            |             |           |                |         |                |                   |      |         |
| Lenvatinib versus placebo   | Progressive disease iodine-refractory differentiated thyroid cancer | PFS        | 3.6 months  | 14.7 months | 0.21 (0.14-0.31) |         |                | Increased toxicity including toxic deaths, downgraded 1 point | -    | 2       |
| SELECT Schlumberger et al, NEJM\(^{18}\) |                      |            |             |           |                |         |                |                   |      |         |
| Sorafenib versus placebo    | Progressive disease iodine-refractory differentiated thyroid cancer | PFS        | 5.8 months  | 5 months   | 0.59 (0.45-0.76) |         |                | 37% versus 26% SAE, downgrade 1 point | -    | 2       |
| DECISION Brose et al, Lancet\(^{19}\) |                        |            |             |           |                |         |                |                   |      |         |

*Unclear toxicity data.

AE, adverse event; EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; MCBS, Magnitude of Clinical Benefit Score; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event.

### Conclusion

Treatment with modern TKIs increased PFS but was usually associated with a significant gain of toxicity. In line with NET and colorectal cancer, the point of discussion not addressed by the ESMO-MCBS is the optimal sequencing and data have to be interpreted with caution concerning progression status and inclusion criteria of the respective trial. For example, in subgroup analyses lenvatinib showed a significant PFS benefit also for sorafenib pretreated patients while prior TKI treatment was not allowed in the sorafenib trial suggesting use of the first compound in this specific setting.

Pancreatic cancer

Data of locally advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC) were subdivided into common strategies for first-line and salvage treatment, respectively (Table 3). For first-line treatment in mPDAC, a comparison between different TKIs is impossible due to the fact of different trial designs and target populations. Thus, the application of the ESMO-MCBS is complicated by methodological issues in this context. While the clinical phase III trial of FOLFIRINOX was an international trial performed in 811 patients in 3 continents, the PRODIGE11 trial was a French phase II trial performed only in 3 cancers centres. In contrast, the PRODIGE11 trial was a French phase II trial performed only in 3 cancers centres. The PRODIGE11 trial was a French phase II trial performed only in 3 cancers centres. Although FOLFIRINOX (gemcitabine) was designed as a clinical phase II trial, which was consecutively extended to a clinical phase III trial, there was no head-to-head comparison. Importantly, the latter trial had no central radiological assessment. Furthermore, the trial was limited to fit (ECOG 0–1) and younger patients, while the MPAC trial included also elderly patients and patients with moderate performance status corresponding to a population closer to a real-world clinical setting.

Although the PRODIGE11 trial was awarded an ESMO-MCBS score of 5, the higher toxicity of the triplet combination has to be taken into account. In terms of efficacy, there is no head-to-head comparison trial of FOLFIRINOX over the gemcitabine plus nab-paclitaxel combination. Thus, the ESMO-MCBS was awarded an ESMO-MCBS score of 3. A bias towards the FOLFIRINOX combination has to be taken into account. In terms of efficacy, FOLFIRINOX was an effective treatment option for younger and fit patients.

For first-line treatment in mPDAC, a comparison between different clinical trials is impossible due to the fact of different trial designs and target populations. Thus, the application of the ESMO-MCBS is complicated by methodological issues in this context. While the clinical phase III trial of FOLFIRINOX was an international trial performed in 811 patients in 3 continents, the PRODIGE11 trial was a French phase II trial performed only in 3 cancers centres. In contrast, the PRODIGE11 trial was a French phase II trial performed only in 3 cancers centres. Although FOLFIRINOX (gemcitabine) was designed as a clinical phase II trial, which was consecutively extended to a clinical phase III trial, there was no head-to-head comparison. Importantly, the latter trial had no central radiological assessment. Furthermore, the trial was limited to fit (ECOG 0–1) and younger patients, while the MPAC trial included also elderly patients and patients with moderate performance status corresponding to a population closer to a real-world clinical setting.

Although the PRODIGE11 trial was awarded an ESMO-MCBS score of 5, the higher toxicity of the triplet combination has to be taken into account. In terms of efficacy, there is no head-to-head comparison trial of FOLFIRINOX over the gemcitabine plus nab-paclitaxel combination. Thus, the ESMO-MCBS was awarded an ESMO-MCBS score of 3. A bias towards the FOLFIRINOX combination has to be taken into account. In terms of efficacy, FOLFIRINOX was an effective treatment option for younger and fit patients.

### Conclusion

Because mPDAC patients have a limited prognosis of <12 months in median OS, there is an urgent need for a head-to-head comparison trial. The authors suggest that mPDAC be the favourable treatment option with FOLFIRINOX being an effective protocol for a certain subgroup of younger and fit patients.
**Table 3** FT of the ESMO-MCBS for the treatment of pancreatic cancer at the Medical University of Vienna

| Analysed treatment | Setting | Primary EP | PFS control | PFS gain | PFS HR | OS control | OS gain | OS HR | Adjustment/remark | MCBS-FT |
|--------------------|---------|------------|-------------|----------|--------|------------|---------|-------|-------------------|---------|
| Gemcitabine ± nab-Paclitaxel* (MPACT) | First-line | Karnofsky index >70% | OS | 6.7 months | 1.8 months | 0.72 | (0.61–0.83) | 5% OS gain at 24 months | 3 | – |
| FOLFRINOX versus gemcitabine* (PRODIGE 4/ACCORD 11) | First-line | ECOG performance status 0-1 | OS | 6.8 months | 4.4 months | 0.57 | (0.45–0.73) | Delayed deterioration of QOL, upgrade 1 point | 5 | – |
| Gemcitabine ± erlotinib* | First-line | OS | 5.9 months | 0.3 months | 0.82 | (0.69–0.99) | 1 | – |
| FOLFOX versus 5FU (CONKO-003) | Second-line after progress to gemcitabine | OS | 3.3 months | 2.6 months | 0.66 | (0.48–0.91) | – | 3 |
| Nal-inototecan + fluorouracil versus nal-inototecan versus fluorouracil (NAPOLI-1) | Second-line after progress to gemcitabine-based therapy | OS | 4.2 months | 1.9 months | 0.67 | (0.49–0.92) | 0.7 months | Non-significant | 2 | 1 |

*Adapted according to Cherny et al.*

EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; MCBS, Magnitude of Clinical Benefit Score; OS, overall survival; PFS, progression-free survival; nal = nanoliposomal.

---

**Head and neck cancer**

Data of recurrent or metastatic head and neck cancer were subdivided into common strategies for first-line and salvage treatment (table 4). A landmark study in this setting was the EXTREME trial published in 2008. This randomised phase III trial investigated the impact of cetuximab as add-on to standard platinum-based chemotherapy followed by a maintenance phase (OS benefit 2.7 months; HR 0.80, 95% CI 0.64 to 0.99) and has most potentially set a new standard of care (MCBS-FT score 3). In second-line afatinib showed only a minor PFS benefit (PFS gain 0.9 months; HR 0.80; 95% CI 0.65 to 0.98) but improvement in QOL was documented resulting in a final MCBS-FT score of 3 (upgrade 1 point). To date, we add data on addition of nivolumab to standard care in second-line or recurrent squamous cell carcinoma of head and neck (CheckMate 141 trial). With an increase in OS to 7.5 months (HR 0.70, 95% CI 0.51 to 0.96), a decrease in daily relevant toxicities (upgrade 1 point) and a substantial improvement of QOL (upgrade 1 point), the assessed MCBS-FT score of 4 may be considered a striking result in terms of clinical benefit. Of note, subgroup analyses demonstrated a particular OS benefit for patients with high PD-L1 expression (10% vs 1% in the control arm; HR 0.64, 95% CI 0.55 to 0.74). In addition, with an increase in OS to 7.5 months (HR 0.70, 95% CI 0.51 to 0.96), a decrease in daily relevant toxicities (upgrade 1 point) and a substantial improvement of QOL (upgrade 1 point), the assessed MCBS-FT score of 4 may be considered a striking result in terms of clinical benefit.
Table 4 FT of the ESMO-MCBS for the treatment of head and neck cancer at the Medical University of Vienna.

| Treated cancer | Setting | OS control | OS gain | PFS control | PFS gain | FT of primary endpoint | Adjustment/remark | MCBS adjustment | MCBS-FT | \(HR\) of OS control | \(HR\) of OS gain |
|---------------|---------|-----------|---------|-------------|----------|------------------------|-------------------|-----------------|---------|-----------------|-----------------|
| Cisplatin ± cetuximab | Previously untreated | OS | 7.4 months | 2.7 months | 0.80 | Decrease QOL, upgrade 1 point | - | - | 3 | - | - |
| Burtness et al, JCO | | | | | | | | | | | |
| Platinum-based CT±cetuximab followed by maintenance (EXTREME) | Previously untreated | OS | 7.4 months | 2.7 months | 0.80 | Decrease QOL, upgrade 1 point | - | - | 3 | - | - |
| Vermorken et al, NEJM | | | | | | | | | | |
| Afatinib versus methotrexate (LUX-Head & Neck 1) | Previously treated with platin-based therapy | OS | 1.7 months | 0.9 months | 0.80 | Improved QOL, upgrade 1 point | - | - | 4* | - | - |
| Machiels et al, Lancet Oncol | | | | | | | | | | |
| Nivolumab versus investigator’s choice (CheckMate 141) | Previously treated with platin-based therapy | OS | 5.1 months | 2.4 months | 0.70 | Less toxicity, improve QOL, upgrade 1 point | - | - | 3 | - | - |
| Ferris et al, NEJM | | | | | | | | | | |

*More mature survival data may improve outcome of MCBS.

**Ovarian cancer**

Data of locally advanced/metastatic ovarian cancer were subdivided into common treatment strategies for first-line, maintenance and salvage treatment (see table 6).36–44

In the first-line setting, the benefit of add-on bevacizumab has been evaluated in the ICON7 trial (including high-risk patients) and the GOG218 trial (incompletely resected patients).36 37 According to the ESMO-MCBS and in line with our clinical experience, the high-risk subgroup of the ICON7 collective achieved a high level of recommendation (ESMO-MCBS score 4) based on a significant OS benefit (7.8 months; HR 0.64, 95% CI 0.48 to 0.85), which was not detected for the low-risk subgroup.36 In contrast, secondary endpoint of OS was only non-significantly improved in the GOG218 trial, thus ESMO-MCBS recommendation level remains moderate (ESMO-MCBS score 3).37 In both trials, QOL was not addressed.

In the setting of recurrent platinum sensitive disease, the addition of bevacizumab to a standard monotherapy achieved a median PFS gain of 4 months (HR 0.48, 95% CI 0.39 to 0.61) and 3.3 months (HR 0.48, 95% CI 0.38 to 0.60), respectively, and in synopsis with an improved QOL a high level of clinical benefit was documented for the second trial (ESMO-MCBS score 4).38–40 The ICON6 trial evaluated addition of cediranib to standard chemotherapy in relapsed, platinum sensitive disease.41 PFS gain was moderate (2.3 months; HR 0.56, 95% CI 0.44 to 0.72) and adverse events slightly elevated (no downgrading) resulting in a MCBS-FT score of 2. In terms of salvage treatment, trabectedin plus liposomal doxorubicin showed a small PFS benefit of median 1.7 and 1.5 months for platinum sensitive and resistant patients, respectively (HR 0.73; 95% CI 0.56 to 0.95 and HR 0.79; 95% CI 0.65 to 0.96) (ESMO-MCBS score 2 and 3).42

Maintenance therapy is currently considered a hot topic in treating advanced ovarian cancer. The landmark trial on olaparib for breast cancer gene (BRCA)-positive ovarian cancer in remission was powered for PFS improvement of QOL for a final MCBS-FT score of 3 (MCBS-FT score 3 for PFS, downgrade 1 point for toxicity, but upgrade 1 point for QOL).32

Furthermore, we have made efforts to assess three publications on bevacizumab for recurrent disease, but none of the trials provided a clinical benefit measurable by the ESMO-MCBS.33–35

**Conclusion:** To date, usability and practicability of the ESMO-MCBS for glioblastoma is not sufficiently clear. Bevacizumab did not show a clinical benefit for recurrent disease in randomised trials according to ESMO-MCBS rating. However, our PDs feel that bevacizumab is needed in specific patients to reduce brain oedema. In a fatal disease like glioblastoma inclusion of improvement of symptoms and possible toxicity/QOL data into treatment decisions appears important and thus the ESMO-MCBS might be a useful tool for further trials and treatment decisions.
**Table 5** FT of the ESMO-MCBS for the treatment of glioblastoma at the Medical University of Vienna

| Analysed treatment | Setting                      | Primary EP | PFS control | PFS gain | PFS HR | OS control | OS gain | OS HR | Adjustment/ remark | MCBS FT |
|--------------------|------------------------------|------------|-------------|----------|--------|------------|---------|-------|-------------------|---------|
| Radiotherapy ± temozolomide<br>Stupp et al, NEJM⁵ | Untreated disease | OS | 12.1 months | 2.5 months | 0.63 (0.52–0.75) | – | 2 |
| Radiotherapy, temozolomide± bevacizumab<br>Gilbert et al, NEJM¹ | Untreated disease | OS, PFS | 7.3 months | 3.4 months | 0.79 (0.66–0.94) | 16 months | – | Non-significant | Deterioration in QOL | – |
| Radiotherapy, temozolomide ± bevacizumab<br>Chinot et al, NEJM² | Untreated disease | OS, PFS | 6.2 months | 4.4 months | 0.64 (0.55–0.74) | 17 months | 0.1 months | Non-significant | Improved QOL, upgrade 1 point; 39% versus 26% SAEs, downgrade 1 point | – |
| Lomustine versus bevacizumab versus bevacizumab + lomustine (BELOB)<br>Taal et al, Lancet Oncol³ | Recurrent disease | OS 9 months | 43% | – | 20% | Not applicable | Combination selected for phase III trial, QOL assessed | NA |
| Lomustine ± bevacizumab (EORTC 26101)<br>Abstract only⁴ | Recurrent disease | OS | 8.6 months | 0.5 months | Non-significant | – | NA |

EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; MCBS, Magnitude of Clinical Benefit Score; OS, overall survival; PFS, progression-free survival; QOL, quality of life.
Table 6 FT of the ESMO-MCBS for the treatment of ovarian cancer at the Medical University of Vienna

| Analysed treatment                                                                 | Setting                                      | EP               | PFS control | PFS gain | PFS HR | OS control | OS gain | OS HR | Adjustment/remark                        | MCBS | MCBS-FT |
|------------------------------------------------------------------------------------|----------------------------------------------|------------------|-------------|----------|--------|------------|---------|-------|-------------------------------------------|------|---------|
| Paclitaxel + carboplatin ± bevacizumab until 18 cycles (ICON7)*                   | High risk, early stage post resection or advanced ovarian or primary peritoneal | PFS all pts      | 22 months   | 1.7 months | 0.81   | 29 months   | 7.8 months | Non-significant | Improvement in survival -> form 2A | 1    | -       |
| Paclitaxel + platin ± bevacizumab until 10 months (GOG218)*                      | Incompletely resected stages III and IV     | PFS              | 10.3 months | 3.9 months | 0.72   | Non-significant | -       | 3    | -                                          | 3    | -       |
| Gemcitabine and carboplatin ± bevacizumab (OCEANS)*                              | Recurrent platinum sensitive                 | PFS              | 8.4 months  | 4 months   | 0.48   | 29 months   | 7.8 months | Non-significant | QOL improved, upgrade 1 point | 3    | -       |
| CT ± bevacizumab (AURELIA)*                                                      | Recurrent platinum sensitive                 | PFS              | 3.4 months  | 3.3 months | 0.48   | QOL data not mature | -       | 4    | -                                          | 4    | -       |
| Cederinib + CT+ maintenance versus CT (ICON6)                                    | Recurrent platinum sensitive                 | PFS              | 8.7 months  | 2.3 months | 0.56   | QOL not improved, downgrade 1 point | -       | 2    | -                                          | 2    | -       |
| Pegylated liposomal doxorubicin ± trabectedin (OVA 301)*                         | Second-line metastatic                      | PFS sens.        | 7.5 months  | 1.7 months | 0.73   | QOL not improved, downgrade 1 point | -       | 3    | -                                          | 3    | -       |
| Olaparib versus placebo*                                                         | BRCA ovarian cancer in remission             | PFS              | 4.3 months  | 6.9 months | 0.18   | QOL not improved, downgrade 1 point | -       | 2    | -                                          | 2    | -       |
| Niraparib versus placebo (ENGOT-OV16/NOVA)                                      | Maintenance for platinum-sensitive recurrent disease | PFS BRCA         | 5 months    | 15.5 months | 0.27   | QOL not improved, downgrade 1 point | -       | 2    | -                                          | 2    | -       |

BRCA, breast cancer gene; CT, chemotherapy; EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; MCBS, Magnitude of Clinical Benefit Score; OS, overall survival; PFS, progression-free survival; resis., platinum-resistant; sens., platinum-sensitive; WT, wild type.

*Adapted according to Cherny et al.
and resulted in a moderate clinical advantage for the patient (ESMO-MCBS grade 2). Further follow-up data would be of interest. In addition, very recently, data on niraparib as maintenance treatment for recurrent, platinum sensitive ovarian cancer have been published in the *New England Journal of Medicine.* While PFS gain was even more impressive in the BRCA germline-mutated cohort (5.5 vs 20.0 months; HR 0.27, 95% CI 0.17 to 0.41), it was less but still relevant in the BRCA wild-type population (3.8 vs 12.9 months; HR 0.38; 0.24–0.59). The calculated MCBS-FT score was 2 for both. Documentation of AEs was increased but mainly affecting the bone marrow.

**Conclusion:** Recommendations resulting of ESMO-MCBS are in line with the clinical practice for treating ovarian cancer, particularly concerning data on bevacizumab. Application of the ESMO-MCBS for maintenance treatment has not been evaluated extensively to date; however, results on poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) appear realistic. Follow-up data and more clinical experience will be of interest. There exist no randomised trials comparing the different approved monotherapies in the relapsed setting.

**Urothelial cancer**

Data of locally advanced/metastatic urothelial cancer were subdivided into common treatment strategies for first line and salvage treatment (see table 7).

In the first-line setting of urothelial cancer randomised trials date back more than 20 years, but there are only a couple of trials with clinical impact. Non-inferiority of cisplatin/gemcitabine in comparison with MVAC was one of the major achievements in the last decades. In 2000, a study addressing this question was published in *JCO* with the primary endpoint being OS. For this study, no clear-OS benefit was demonstrated, despite two updates being published in the following. However, there was consistent non-inferiority documented with a favourable toxicity profile for cisplatin/gemcitabine. We assessed this trial with form 2C for a MCBS-FT score of 4 in terms of clinical benefit. Next, high-dose MVAC is still an option for young and fit patients. In a trial matching this regimen with MVAC standard an OS benefit was observed (>5% increase in 3 year OS; HR 0.76, 95% CI 0.58 to 0.99) (MCBS-FT score 3). A comparison of this regimen with cisplatin/gemcitabine is not available.

The study on vinflunine by Bellmunt et al addressed the key question if chemotherapy is superior to best supportive care in this setting. Long-term results showed only a non-significant OS improvement (ESMO-MCBS not applicable), thus no further information is added by use of the scoring system in this particular setting. Randomised data on immune checkpoint inhibitors are currently not yet available but a wide range of trials testing PD-1/ PD-L1 inhibitors are ongoing.

**Conclusion:** ESMO-MCBS assessment of the first-line standard treatment appears reasonable and feasible. In the salvage setting, there is a lack on randomised data

---

**Table 7.** FT of the ESMO-MCBS for the treatment of urothelial cancer at the Medical University of Vienna

| Analysed treatment | Primary EP Setting | Setting | OS (months) | OS HR | MCBS-FT | Adjustment/remark |
|--------------------|--------------------|---------|-------------|-------|---------|-------------------|
| Cisplatin + gemcitabine versus MVAC | von der Maase et al, JCO | OS; 12.7 | 0.87 | NA | 4 | Non-significant less toxicity with new combination |
| Cisplatin + gemcitabine ± paclitaxel (EORTC 30987) | Bellmunt et al, JCO | OS; 7.6 | 0.7 | NA | 3 | 3.1 months Non-significant Increase in response rate |
| High-dose intensified MVAC versus classic MVAC | Sternberg et al, JCO | OS | 14.9 | 0.76 | NA | Score based on 3 year OS (>3%); Non-significant |
| Vinflunine versus best supportive care | Bellmunt et al, JCO | OS | 4.6 | NA | 3 | 2.3 months Non-significant |

EP: endpoint; ESMO: European Society for Medical Oncology; FT: field testing; MCBS: Magnitude of Clinical Benefit Score; MVAC: methotrexate, vinblastine, doxorubicin; OS: overall survival; PFS: progression-free survival.
and particularly data on checkpoint inhibitors need to be awaited.

**Soft tissue sarcoma**

Data of locally advanced/metastatic STS were subdivided into common treatment strategies for GIST and STS, respectively (see table 8).55–63

GIST: While imatinib remains the undisputable standard of care for untreated advanced/metastatic GIST with corresponding trials in the past having concentrated mainly on different dosing strategies,54–66 there are important placebo-controlled data on sunitinib for second line and regorafenib for third line.53,54 Both trials resulted in an ESMO-MCBS score of 3 supporting the use of these compounds in the respective setting.

STS: We have identified two trials assessing the addition of ifosfamide to doxorubicin for first-line advanced/metastatic STS. Both trials did not meet their predefined primary endpoints. Consequently, the ESMO-MCBS scoring system was not applicable and results do not support treatment intensification in this scenario in general.53,56 However, if a response is needed, this combination is of value in selected histologies. Liposomal formulation of doxorubicin might reduce toxicity in selected patients (MCBS-FT 1–3).57 Finally, recently promising data on addition of anti-PDGFRe antibody olaratumab to doxorubicin have been published.68 Olaratumab/doxorubicin resulted in a significant improvement of secondary endpoint OS (+11.8 months; HR 0.46, 95% CI 0.30 to 0.71) and the corresponding MCBS-FT score of 4 reflects clearly the high clinical benefit to be expected of this combination.

In the setting of relapsed STS data of the PALETTE trial showed evidence for a benefit of pazopanib with a median PFS plus of 3.0 months (HR 0.31, 95% CI 0.24 to 0.40) (MCBS-FT score 3).59 The combination of gemcitabine/dacarbazine versus gemcitabine monotherapy reached a high level of recommendation by means of the ESMO-MCBS due to a 8.6 months increase in median survival (HR 0.56; 95% CI 0.36 to 0.9) (MCBS-FT score 4).60

Trabectedin for salvage treatment in STS has been approved in Europe and the USA based on trials with a low maximum clinical benefit score of 2 (MCBS-FT).61,62 The earlier trial compared trabectedin 3-weekly versus weekly and underlined activity of this compound in STS; however, the clinical benefit assessed by ESMO-MCBS appeared marginal (MCBS-FT score 2).61 A subsequent randomised trial versus dacarbazine was powered for OS but did only improve PFS and was thus a negative trial per endpoint (ESMO-MCBS not applicable).62 In 2016, first data on eribulin (versus dacarbazine) were published and followed with great interest. OS was 13.5 months in median versus 11.5 months (HR 0.77, 95% CI 0.62 to 0.95) (MCBS-FT score 2).63 Remarkably, in a planned subgroup analysis for liposarcoma median OS was 8.4 months in the standard group versus 15.6 months in the experimental arm (OS gain 7.2 months; HR 0.51, 95% CI 0.35 to 0.75) supporting the use of eribulin in this subgroup (MCBS-FT score 4).

**Conclusion:** In GIST, clinical benefit as assessed by the ESMO-MCBS displays well the real-life situation. Clinical practicability of the MCBS in ‘non-GIST’ STS is very limited. The tumour entity ‘soft tissue sarcoma’ encompasses more than 50 different histologies that does not allow the application of the MCBS in this heterogeneous disease. In addition, the example of trabectedin shows that in some situations a certain control arm as 3-weekly versus weekly application might make sense in the clinical setting but undermines the result if evaluated with the ESMO-MCBS.61 Equally, in the second study on trabectedin, ESMO-MCBS was not applicable as the study failed to meet its primary endpoint due to a PFS but not OS surplus (primary endpoint OS).62 However, in ‘real life’ prolonged and sustained disease stabilisation is of definitive benefit for the individual patient.

**DISCUSSION**

In the past few months, we have been evaluating the feasibility and applicability of the ESMO-MCBS in the daily routine of the Clinical Division of Oncology at the MUV, a tertiary referral centre for medical oncological care. In our pilot analysis on common tumour subtypes, we have demonstrated that the ESMO-MCBS scores are consistent with our practice in the majority of malignancies and treatment settings and are particularly confirming our first-line standards for frequent tumour entities including metastatic breast cancer, colorectal cancer or lung cancer.3 However, there were certain limitations detected including salvage treatment situations with a lack of randomised data and therapeutic decisions being mostly based on single arm phase II trials or tumour entities involving cascade like treatment settings.

In the current analysis, we report data on infrequent tumour entities. While in the early stage of development of the ESMO-MCBS by the taskforce only a careful selection of studies for a proof of principle analysis has been aimed at, we have now also included entities with basically no prior experience of usability of the ESMO-MCBS such as NET, thyroid cancer, glioblastoma, urothelial cancer, STS, and head and neck cancer.

In line with our recent experience in common tumour entities, most scores assessed by our field testing corresponded with the daily clinical practice at our institution and supported both the use of the ESMO-MCBS and our current treatment standards. Interestingly, less frequent tumour entities generally scored lower than entities analysed before, but the clinical benefit appeared to be depicted adequately whenever data from randomised studies were available. In NETs, for example, all current trials resulted in a MCBS-FT score of 2 or 3 reflecting the moderate PFS benefit aligned with a favourable toxicity profile quintessential for the treatment of this specific disease.6,15 However, a maximum score of 3 is clearly inferior to results achieved for metastatic breast or colorectal...
### Table 8: FT of the ESMO-MCBS for the treatment of GIST and soft tissue sarcomas at the Medical University of Vienna

| Analysed treatment | Setting | Primary EP | PFS control | PFS gain | PFS HR | OS control | OS gain | OS HR | Adjustment/remark | MCBS | MCBS-FT |
|--------------------|---------|------------|-------------|----------|--------|------------|---------|--------|-------------------|------|---------|
| Sunitinib versus placebo* Demetri et al. | Second-line advanced GIST after imatinib | TTP | 6.4 weeks | 16.9 weeks | 0.33 (0.23–0.47) | 3 | – |
| Regorafenib versus Placebo (GRID)* Demetri et al. | third-line advanced GIST after imatinib and sunitinib | PFS | 0.9 months | 3.7 months | 0.27 (0.19–0.39) | 3 | – |
| Doxorubicin + ifosfamide (EORTC 62012) Judson et al. | Previously untreated soft tissue sarcoma | OS | 13 months | 1.5 months | Non-significant Results do no support intensified treatment | – | NA |
| High-dose doxorubicin + ifosfamide versus doxorubicin Maurel et al. | Previously untreated soft tissue sarcoma | PFS | 26 weeks | Non-significant Results do no support intensified treatment | – | NA |
| Pegylated liposomal doxorubicin versus doxorubicin Judson et al. Tap et al. | Naive or pretreated advanced soft tissue sarcoma | RR | 9% | 1% | Less toxicity, upgrade 1–2 points | – | 1–3 |
| Doxorubicin +/- olaratumab | Previously untreated soft tissue sarcoma | PFS | 4.1 months | 2.5 months | 0.67 (0.44–1.02) | 14.7 months | 11.8 months | 0.46 (0.30–0.71) | Improvement in survival -> form 2a | – | 4 |
| Pazopanib versus placebo (PALETTE)* van der Graaf et al. | Previously treated soft tissue sarcoma | PFS | 1.6 months | 3.0 months | 0.31 (0.24–0.4) | – | – |
| Gemcitabine + dacarbazine versus gemcitabine Garcia-Dei-Muro et al. | Previously treated soft tissue sarcoma | PFS | 2 months | 2.2 months | 0.58 (0.39–0.86) | 8.2 months | 8.6 months | 0.56 (0.36–0.9) | Improvement in survival -> form 2a | – | 4 |
| Trabectedin q21 versus trabectedin q28 d1+8+15 | Previously treated liposarcoma, leiomyosarcoma | TTP | 2.3 months | 1.4 months | 0.73 (0.55–0.97) | – | Data support use of trabectedin | – | 2 |
| Trabectedin versus dacarbazine Demetri et al. | Previously treated liposarcoma, leiomyosarcoma | OS | 1.5 months | 2.7 months | 0.55 (0.44–0.70) | 12.4 months | 0.5 months Non-significant PFS as second endpoint improved | – | NA |
| Eribulin versus dacarbazine Schöffski et al. | Previously treated liposarcoma, leiomyosarcoma | OS | – | – | – | 11.5 months | 2 months | 0.77 (0.62–0.95) | – | 2 |

*Adapted according to Cherny et al.
†Unclear toxicity data.
EP, endpoint; ESMO, European Society for Medical Oncology; FT, field testing; GIST, gastrointestinal stromal tumours; MCBS, Magnitude of Clinical Benefit Score; OS, overall survival; PFS, progression-free survival; TTP, time to progression.
cancer. This fact might possibly be related to the inferior power of trials in infrequent diseases. In addition, we could identify several trials relevant to our practice that added new data to the field but per definition did not meet their statistical endpoint. As outlined in the primary publication by the ESMO taskforce, those trials are not assessable by the ESMO-MCBS even if they result in potentially clinical relevant prolongation of PFS/OS (eg, trabectedin for STS).

As of 2017 and in view with the increasing experience and knowledge on immunomodulatory treatment strategies, it appears of pre-eminent public interest to assess the applicability of the ESMO-MBCS on those particular compounds. It was thus encouraging to observe that checkpoint inhibitors seem to do extremely well in the ESMO-MCBS scoring system. In the current analysis, we have assessed new data on nivolumab for second-line head and neck cancer. Results were convincing with a MCBS-FT score of 4 (higher than the first-line data with a MCBS-FT of 3) based on an increase in PFS and superior QOL during therapy. It appears that checkpoint inhibitors fully underline the concept of the ESMO-MCBS due to the fact that they are usually characterised by positive efficacy data paired with reduction in toxicities and consequently an improvement in QOL. Similar results were also obtained in our analysis for common entities exemplified by PD-1 inhibition in non-small cell lung cancer and renal cell cancer providing a stringent concept for the use of the ESMO-MCBS in the era of immunomodulatory treatment.

The limitations of the ESMO-MCBS were clinical settings where a cascade-like treatment algorithm is standard of care. While the ESMO-MCBS in its current version allows assessment of multiple studies in form of meta-analyses, it is not possible to interconnect or combine the results of two or more distinct trials. Thus, due to a lack of proper data, the ESMO-MCBS does not support treatment decisions in these specific scenarios. While this was already obvious in our pilot trial on frequent entities including renal cell and colorectal cancers, we have observed the same phenomenon now for NET and thyroid cancer.

Notably, the ESMO taskforce plans to re-evaluate the ESMO-MCBS on a regular basis and this caveat is already part of current considerations underlining the importance of the ESMO-MCBS representing a dynamic tool.

In addition, the results of the ESMO-MCBS appear less useful in situations where former disease ‘entities’ are becoming subdivided into subsets in which certain therapies are efficacious, whereas they are not in others with STS being an excellent example. Here, the ESMO-MCBS will have to await further clarification regarding disease subsets versus treatment options. Finally, in such scenarios in which trials of most efficacious treatments are missing (eg, in the first-line treatment of pancreatic cancer), the magnitude of clinical benefit has to remain open until further trials will be performed.

To conclude, the ESMO-MCBS appears to be unique due to the fact that it is based on the clinical benefit to be expected for the individual patient. While we cannot provide a 100% complete work-up of all oncological treatment options, our data represent clearly a consistent real-life experience in a university hospital setting. Our results encourage the use of the ESMO-MCBS in clinical routine—irrespective of the specific work environment—as it is easy to use and helps to interpret and categorise original data with a focus on an individual patient’s needs. In addition, ESMO plans to include ESMO-MCBS scores in all new clinical practice guidelines and assess scores of European Medicines Agency approvals. It will be interesting to learn about further amendments of the scoring systems, as by now major efforts are being made in this direction acknowledging and addressing potential caveats and points of discussions in the use of the ESMO-MCBS V1.0. The ESMO-MCBS V1.1 is currently being field tested by the taskforce and first results will be available in 2017.

Contributors All authors fulfills the criteria for authorship and have read and approved the final version of the manuscript.

Competing interests GWP has received honoraria for lectures by Merck Serono, Amgen, Bayer, Servier, Lilly, Celgene, Roche and Sanofi Aventis; TF has received honoraria or research grants from MSD, Merck, BMS, Pfizer, Sanzoz and Astra Zeneca; MP has received research support from Boehringer-Ingeheim, GlaxoSmithKline, Merck Sharp & Dome and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMS Contrast, GlaxoSmithKline, Mundipharma, Roche and Astra Zeneca; GJL has received research support from Pierre Fabre and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb and Roche; TB has received personal fees from Amgen (lecture fee and advisory board), personal fees from Bayer (lecture fee and advisory board), personal fees from Eisai (lecture fee and advisory board), personal fees from Eli Lilly (lecture fee and advisory board), personal fees from Novartis (lecture fee and advisory board), personal fees from PharmaMar (lecture fee) and personal fees from Roche (lecture fee) outside the submitted work. CCZ has received honoraria by Bristol Myers-Squibb, Merck Sharp Dohme, Novartis, Roche, Astra Zeneca, Ariad and Imugene. All remaining authors have declared no conflict of interest.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547–73.
2. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a Conceptual Framework to assess the value of Cancer treatment Options. J Clin Oncol 2015;33:2563–77.
3. http://app.drugabacus.org/abacus-mskcc
4. http://www.esmo.org/Policies/Magnitude-of-Clinical-Benefit-Scale/
5. Kiesewetter B, Raderer M, Steger GG, et al. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in Daily practice: a Single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066.
6. Giuliani J, Remo A, Bonetti A. See comment in PubMed Commons below The European Society for Medical Oncology Magnitude of

Kiesewetter B, et al. ESMO Open 2017;2:e000166. doi:10.1136/esmoopen-2017-000166

13
Clinical Benefit Scale (ESMO-MCBS) applied to Pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for Advanced non-small cell lung Cancer with activating Epidermal growth factor receptor mutations. Expert Rev Pharmacoecon Outcomes Res 2016;16:1–4.

WHO. Stewart BW, Wild CP, eds. World Cancer Report, Lyon, France: International Agency for Research on Cancer, 2014.

Caplin ME, Pavel M, Čvicka JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371:224–32.

Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.

Yao JC, Fazio N, Sengelov L, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumors of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016;387:968–77.

Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.

Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of Advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the Randomized, phase III RADIANT-3 study. J Clin Oncol 2016;34:9063–13 (Epub ahead of print).

Pavel ME, Harbison CD, Baudin E, et al. Everolimus long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:171–80.

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.

Faivre S, Niccoli P, Castellano D, et al. Sunititin in pancreatic neuroendocrine tumors: updated Progression-Free Survival and final overall survival from a phase III Randomized Study. Ann Oncol 2016;mdw561 (Epub ahead of print).

Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid Cancer. J Clin Oncol 2013;31:3639–46.

Wells SA, Robson CG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid Cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134–41.

Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid Cancer. N Engl J Med 2015;372:621–30.

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic Cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–703.

Conroy T, Desaigene F, Ychou M, et al. FOLFIRINOX versus gemcitabine in metastatic pancreatic Cancer. N Engl J Med 2011;364:1817–25.

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with Advanced pancreatic Cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–6.

Oettel H, Riess H, Stieler JM, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy [LUX-Head & neck 1]: an open-label, randomised phase 3 trial. Lancet Oncol 2015;16:583–94.

Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1868–76.

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.

Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. J Clin Oncol 2014;32:699–708.

Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22.

Taal W, Oosterkamp HM, Walsenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15:943–53.

Driven L, van den Bent MJ, Bottomley A, et al. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 2015;51:1321–30.

Wick W, Brandes AA, Gorlia T, et al. Lb-08phase III trial exploring THE combination of bevacizumab and lomustine in patients with first recurrences of a glioblastoma: the e26110 trial. Neuro Oncol 2015;17:v1–v11.

Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian Cancer. N Engl J Med 2011;365:2484–96.

Basilico RA, Brady MF, Travaglini MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian Cancer. N Engl J Med 2016;375:2473–83.

Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube Cancer. J Clin Oncol 2012;30:2039–45.

Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian Cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302–8.

Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant recurrent ovarian Cancer: J Clin Oncol 2014;32:1306–16.

Ledermann JA, Emebolton AC, Raja F, et al. Cedinabin in patients with relapsed platinum-sensitive ovarian Cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;387:1066–74.

Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian Cancer. J Clin Oncol 2010;28:3107–14.

Ledermann JA, Carver JG, Kafka A, et al. Ovarian Cancer with platinum-sensitive relapsed serous ovarian Cancer: a preplanned retrospective analysis of outcomes by BRCA1 status in a randomised phase 2 trial. Lancet Oncol 2014;15:852–61.

Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance therapy in Platinum-Sensitive, recurrent ovarian Cancer. N Engl J Med 2018;379:2154–64.

Liu MC, Morrissey CT, Meers SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder Cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3086–77.

van der Maas H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder Cancer. J Clin Oncol 2005;23:4602–8.

Roberts JT, van der Maas H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder Cancer. Ann Oncol 2006;17(Suppl 5):v118–v122.

Bellmunt J, van der Maas H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine and cisplatin in patients with locally advanced or metastatic urothelial Cancer without prior systemic therapy: eortc Intergroup Study 30987. J Clin Oncol 2012;30:1107–13.

Stembridge CN, de Mulder PH, Schomagel J, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant
human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: european Organization for Research and treatment of Cancer protocol no. 30924. J Clin Oncol 2001;19:2638–46.

50. Sternberg CN, de Mulder P, Schormagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–4.

51. Bellmunt J, Théodore C, Demkov T, et al. Phase II trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454–61.

52. Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013;24:1466–72.

53. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38.

54. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302.

55. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase II trial. Lancet Oncol 2014;15:415–23.

56. Maurel J, López-Pousa A, de Las Peñas R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II trial of the Spanish group for research on sarcomas. J Clin Oncol 2009;27:1893–8.

57. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft tissue and bone Sarcoma Group. Eur J Cancer 2001;37:870–7.

58. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016;388:488–97.

59. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–86.

60. García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;29:2528–33.

61. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188–96.

62. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III Randomized Multicenter clinical trial. J Clin Oncol 2016;34:786–93.

63. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629–37.

64. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34.

65. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32.

66. Gastrointestinal stromal tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247–53.